Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC

IF 3 Q2 ONCOLOGY
Anne Mc Leer PhD , Julie Mondet PharmD, PhD , Nelly Magnat MSc , Mailys Mersch MSc , Diane Giovannini MD , Camille Emprou MD , Anne-Claire Toffart MD, PhD , Nathalie Sturm MD, PhD , Sylvie Lantuéjoul MD, PhD , David Benito PhD
{"title":"Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC","authors":"Anne Mc Leer PhD ,&nbsp;Julie Mondet PharmD, PhD ,&nbsp;Nelly Magnat MSc ,&nbsp;Mailys Mersch MSc ,&nbsp;Diane Giovannini MD ,&nbsp;Camille Emprou MD ,&nbsp;Anne-Claire Toffart MD, PhD ,&nbsp;Nathalie Sturm MD, PhD ,&nbsp;Sylvie Lantuéjoul MD, PhD ,&nbsp;David Benito PhD","doi":"10.1016/j.jtocrr.2024.100714","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div><em>RET</em> rearrangements occur in 1% to 2% NSCLCs. Since no clinically validated RET antibody is currently available, fluorescence in situ hybridization (FISH) is often used as a screening tool to identify patients likely to benefit from RET-targeted therapy. In this study, we performed a comprehensive review of publications in which <em>RET</em>-rearrangement testing was performed by FISH and compared the methods and results with our data.</div></div><div><h3>Methods</h3><div>The findings of an electronic search for publications using <em>RET</em>-FISH in lung cancer were compared with the results obtained at the Grenoble University Hospital where 784 <em>EGFR</em><em>-</em>, <em>KRAS</em><em>-</em>, <em>ALK</em>-, and <em>ROS1</em>-negative NSCLCs were tested by <em>RET</em> break-apart FISH and confirmed by RNA-sequencing (RNA-seq).</div></div><div><h3>Results</h3><div>Out of the 85 publications using <em>RET</em>-FISH analysis, 52 pertained to patients with lung cancer. The most often used positivity threshold was 15%. Six publications compared <em>RET</em>-FISH with at least one other molecular technique on at least eight samples, and the concordance was variable, from 5.9% to 66.7% for FISH-positive cases. Regarding our data, out of the 784 analyzed samples, 32 (4%) were positive by <em>RET</em>-FISH. The concordance between <em>RET</em>-FISH and RNA-seq in <em>RET</em>-FISH positive samples was 69%.</div></div><div><h3>Conclusions</h3><div>Overall, both existing literature and our data suggest that <em>RET</em>-FISH testing can be used for rapid screening of <em>RET</em> rearrangements in NSCLC. Nevertheless, using an orthogonal technique such as RNA-seq to confirm <em>RET</em>-FISH-positive cases is essential for ensuring that only patients likely to benefit from <em>RET</em>-target therapy receive the treatment.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100714"},"PeriodicalIF":3.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000845","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

RET rearrangements occur in 1% to 2% NSCLCs. Since no clinically validated RET antibody is currently available, fluorescence in situ hybridization (FISH) is often used as a screening tool to identify patients likely to benefit from RET-targeted therapy. In this study, we performed a comprehensive review of publications in which RET-rearrangement testing was performed by FISH and compared the methods and results with our data.

Methods

The findings of an electronic search for publications using RET-FISH in lung cancer were compared with the results obtained at the Grenoble University Hospital where 784 EGFR-, KRAS-, ALK-, and ROS1-negative NSCLCs were tested by RET break-apart FISH and confirmed by RNA-sequencing (RNA-seq).

Results

Out of the 85 publications using RET-FISH analysis, 52 pertained to patients with lung cancer. The most often used positivity threshold was 15%. Six publications compared RET-FISH with at least one other molecular technique on at least eight samples, and the concordance was variable, from 5.9% to 66.7% for FISH-positive cases. Regarding our data, out of the 784 analyzed samples, 32 (4%) were positive by RET-FISH. The concordance between RET-FISH and RNA-seq in RET-FISH positive samples was 69%.

Conclusions

Overall, both existing literature and our data suggest that RET-FISH testing can be used for rapid screening of RET rearrangements in NSCLC. Nevertheless, using an orthogonal technique such as RNA-seq to confirm RET-FISH-positive cases is essential for ensuring that only patients likely to benefit from RET-target therapy receive the treatment.
与其他技术相比,荧光原位杂交法检测 NSCLC 转染过程中的基因重组情况
1%至2%的NSCLC会出现RET重排。由于目前还没有经过临床验证的 RET 抗体,荧光原位杂交(FISH)通常被用作筛选工具,以确定可能从 RET 靶向治疗中获益的患者。在本研究中,我们对通过 FISH 进行 RET 重排检测的文献进行了全面回顾,并将其方法和结果与我们的数据进行了比较。在格勒诺布尔大学医院,784 例 EGFR、KRAS、ALK 和 ROS1 阴性 NSCLC 接受了 RET 重排 FISH 检测,并通过 RNA 序列(RNA-seq)进行了确认。结果在 85 篇使用 RET-FISH 分析的文献中,52 篇与肺癌患者有关。最常用的阳性阈值为 15%。有 6 篇文献对至少 8 个样本的 RET-FISH 与至少一种其他分子技术进行了比较,两者的一致性不尽相同,FISH 阳性病例的一致性从 5.9% 到 66.7% 不等。就我们的数据而言,在 784 份分析样本中,有 32 份(4%)RET-FISH 阳性。在RET-FISH阳性样本中,RET-FISH与RNA-seq的一致性为69%。结论总的来说,现有文献和我们的数据都表明,RET-FISH检测可用于快速筛查NSCLC中的RET重排。然而,使用 RNA-seq 等正交技术确认 RET-FISH 阳性病例对于确保只有可能从 RET 靶向治疗中获益的患者接受治疗至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信